|
US7291615B2
(en)
|
2003-05-01 |
2007-11-06 |
Bristol-Myers Squibb Company |
Cyclic derivatives as modulators of chemokine receptor activity
|
|
CN1933847A
(zh)
*
|
2004-01-16 |
2007-03-21 |
密歇根大学董事会 |
Smac肽模拟物及其应用
|
|
BRPI0507482A
(pt)
*
|
2004-02-05 |
2007-07-17 |
Novartis Ag |
combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap
|
|
CA2558615C
(en)
|
2004-03-23 |
2013-10-29 |
Genentech, Inc. |
Azabicyclo-octane inhibitors of iap
|
|
EP2253614B1
(en)
*
|
2004-04-07 |
2012-09-19 |
Novartis AG |
Inhibitors of IAP
|
|
MXPA06014969A
(es)
*
|
2004-07-02 |
2007-02-08 |
Genentech Inc |
Inhibidores de iap.
|
|
EP1773766B1
(en)
|
2004-07-15 |
2014-04-02 |
Tetralogic Pharmaceuticals Corporation |
Iap binding compounds
|
|
ATE477254T1
(de)
*
|
2004-12-20 |
2010-08-15 |
Genentech Inc |
Pyrrolidine als inhibitoren von iap
|
|
BRPI0607988A2
(pt)
*
|
2005-02-25 |
2009-10-27 |
Tetralogic Pharmaceuticals |
composto, composição farmacêutica, e método para induzir apoptose em uma célula
|
|
DE102005017116A1
(de)
*
|
2005-04-13 |
2006-10-26 |
Novartis Ag |
Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)
|
|
US7772177B2
(en)
|
2005-05-18 |
2010-08-10 |
Aegera Therapeutics, Inc. |
BIR domain binding compounds
|
|
AU2006254538A1
(en)
|
2005-05-25 |
2006-12-07 |
2Curex Aps |
Compounds modifying apoptosis
|
|
US8318717B2
(en)
|
2005-05-25 |
2012-11-27 |
2Curex |
Compounds modifying apoptosis
|
|
US20100256046A1
(en)
*
|
2009-04-03 |
2010-10-07 |
Tetralogic Pharmaceuticals Corporation |
Treatment of proliferative disorders
|
|
JP2009512719A
(ja)
|
2005-10-25 |
2009-03-26 |
アエゲラ セラピューティクス インコーポレイテッド |
Iapbirドメイン結合化合物
|
|
CN101374829A
(zh)
*
|
2005-12-19 |
2009-02-25 |
健泰科生物技术公司 |
Iap的抑制剂
|
|
ES2684120T3
(es)
|
2005-12-20 |
2018-10-01 |
Novartis Ag |
Combinación de un inhibidor de IAP y un taxano
|
|
CA2634743C
(en)
*
|
2005-12-23 |
2014-07-29 |
Zealand Pharma A/S |
Modified lysine-mimetic compounds
|
|
TWI543988B
(zh)
|
2006-03-16 |
2016-08-01 |
科學製藥股份有限公司 |
結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物
|
|
AU2007250443B2
(en)
*
|
2006-05-16 |
2013-06-13 |
Pharmascience Inc. |
IAP BIR domain binding compounds
|
|
WO2008014252A2
(en)
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Iap inhibitors
|
|
US20100144650A1
(en)
*
|
2006-07-24 |
2010-06-10 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
AR063943A1
(es)
*
|
2006-07-24 |
2009-03-04 |
Tetralogic Pharmaceuticals Cor |
Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer.
|
|
WO2008014238A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
WO2008014240A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
WO2008014236A1
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
PE20110224A1
(es)
|
2006-08-02 |
2011-04-05 |
Novartis Ag |
PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO
|
|
RU2009117701A
(ru)
|
2006-10-12 |
2010-11-20 |
Новартис АГ (CH) |
Производные пирролидина в качестве ингибиторов iap
|
|
JP5394249B2
(ja)
|
2006-11-28 |
2014-01-22 |
ノバルティス アーゲー |
Iap阻害剤とflt3阻害剤の組合せ剤
|
|
JP2010513561A
(ja)
*
|
2006-12-19 |
2010-04-30 |
ジェネンテック, インコーポレイテッド |
Iapのイミダゾピリジンインヒビター
|
|
ES2558856T3
(es)
|
2006-12-21 |
2016-02-09 |
Zealand Pharma A/S |
Síntesis de compuestos de pirrolidina
|
|
AU2008240153B2
(en)
*
|
2007-04-12 |
2013-01-31 |
Joyant Pharmaceuticals, Inc. |
SMAC mimetic dimers and trimers useful as anti-cancer agents
|
|
CN101687787A
(zh)
|
2007-04-30 |
2010-03-31 |
健泰科生物技术公司 |
Iap的抑制剂
|
|
JP2010528587A
(ja)
*
|
2007-05-07 |
2010-08-26 |
テトラロジック ファーマシューティカルズ コーポレーション |
アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてTNFα遺伝子の発現を用いる方法
|
|
KR20100110870A
(ko)
*
|
2008-01-11 |
2010-10-13 |
제넨테크, 인크. |
Iap의 억제제
|
|
NZ590550A
(en)
|
2008-08-02 |
2013-05-31 |
Genentech Inc |
Inhibitors of Apoptosis (IAP) for treating cancer
|
|
US20110218211A1
(en)
*
|
2008-08-16 |
2011-09-08 |
Genentech, Inc. |
Azaindole inhibitors of iap
|
|
US8283372B2
(en)
|
2009-07-02 |
2012-10-09 |
Tetralogic Pharmaceuticals Corp. |
2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
|
|
TW201109335A
(en)
|
2009-08-04 |
2011-03-16 |
Takeda Pharmaceutical |
Heterocyclic compounds
|
|
CN105646471A
(zh)
|
2009-08-12 |
2016-06-08 |
诺华股份有限公司 |
细胞凋亡蛋白抑制剂的固体口服制剂和晶形
|
|
US20120196793A1
(en)
*
|
2009-09-18 |
2012-08-02 |
Firestone Brant G |
Biomarkers for iap inhibitor compounds
|
|
CN102050867A
(zh)
*
|
2009-11-10 |
2011-05-11 |
上海艾力斯医药科技有限公司 |
四肽类似物、制备方法及其应用
|
|
EP2534170B1
(en)
|
2010-02-12 |
2017-04-19 |
Pharmascience Inc. |
Iap bir domain binding compounds
|
|
EP3608317A1
(en)
|
2012-01-12 |
2020-02-12 |
Yale University |
Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
|
|
US8859541B2
(en)
*
|
2012-02-27 |
2014-10-14 |
Boehringer Ingelheim International Gmbh |
6-alkynylpyridines
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
CA2974651A1
(en)
|
2014-01-24 |
2015-07-30 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Smc combination therapy for the treatment of cancer
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
HK1247204A1
(zh)
|
2015-01-20 |
2018-09-21 |
Arvinas Operations, Inc. |
用於雄激素受体的靶向降解的化合物和方法
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
GB201506872D0
(en)
*
|
2015-04-22 |
2015-06-03 |
Ge Oil & Gas Uk Ltd |
Novel compounds
|
|
EP3302482A4
(en)
|
2015-06-05 |
2018-12-19 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
WO2017011590A1
(en)
*
|
2015-07-13 |
2017-01-19 |
Arvinas, Inc. |
Alanine-based modulators of proteolysis and associated methods of use
|
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
BR112018008918A8
(pt)
|
2015-11-02 |
2019-02-26 |
Univ Yale |
compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
|
|
JP7286539B2
(ja)
|
2016-11-01 |
2023-06-05 |
アルビナス・オペレーションズ・インコーポレイテッド |
タウタンパク質標的化protac、および関連使用方法
|
|
DK3689868T3
(da)
|
2016-12-01 |
2024-01-02 |
Arvinas Operations Inc |
Tetrahydronaphthalen- og tetrahydroisoquinolinderivater som østrogenreceptordegraderende midler
|
|
CN110753693A
(zh)
|
2016-12-23 |
2020-02-04 |
阿尔维纳斯运营股份有限公司 |
Egfr蛋白水解靶向嵌合分子和相关使用方法
|
|
AU2017382436C1
(en)
|
2016-12-23 |
2021-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of Rapidly Accelerated Fibrosarcoma polypeptides
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
EP3573977A4
(en)
|
2017-01-26 |
2020-12-23 |
Arvinas Operations, Inc. |
Modulators of estrogen receptor proteolysis and associated methods of use
|
|
EP3618847B1
(en)
|
2017-05-05 |
2021-04-07 |
Zealand Pharma A/S |
Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
|
|
EP3658235A1
(en)
*
|
2017-07-25 |
2020-06-03 |
Hepagene Therapeutics, Inc. |
Dimeric peptide inhibitors of apoptosis proteins
|
|
EP3658158A4
(en)
*
|
2017-07-27 |
2021-04-14 |
The National Institute for Biotechnology in the Negev Ltd. |
SMAC / YLDIABLO INHIBITORS TO TREAT CANCER
|
|
WO2019099926A1
(en)
|
2017-11-17 |
2019-05-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
|
CN119569702A
(zh)
|
2018-04-04 |
2025-03-07 |
阿尔维纳斯运营股份有限公司 |
蛋白水解调节剂及相关使用方法
|
|
WO2020041331A1
(en)
|
2018-08-20 |
2020-02-27 |
Arvinas Operations, Inc. |
Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
|
|
US11912699B2
(en)
|
2019-07-17 |
2024-02-27 |
Arvinas Operations, Inc. |
Tau-protein targeting compounds and associated
|
|
IL290789B2
(en)
|
2019-08-26 |
2025-09-01 |
Arvinas Operations Inc |
Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
|
|
JP2023539663A
(ja)
|
2020-08-28 |
2023-09-15 |
アルビナス・オペレーションズ・インコーポレイテッド |
急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法
|
|
CN116390916A
(zh)
|
2020-09-14 |
2023-07-04 |
阿尔维纳斯运营股份有限公司 |
用于靶向降解雌激素受体的化合物的结晶形式
|
|
US11957759B1
(en)
|
2022-09-07 |
2024-04-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
|
|
WO2024159164A2
(en)
|
2023-01-26 |
2024-08-02 |
Arvinas Operations, Inc. |
Cereblon-based kras degrading protacs ans uses related thereto
|